135 related articles for article (PubMed ID: 7527306)
1. Plasma vs whole blood for therapeutic drug monitoring of patients receiving FK 506 for immunosuppression.
Winkler M; Ringe B; Baumann J; Loss M; Wonigeit K; Pichlmayr R
Clin Chem; 1994 Dec; 40(12):2247-53. PubMed ID: 7527306
[TBL] [Abstract][Full Text] [Related]
2. Monitoring FK 506 concentrations in plasma and whole blood.
Jusko WJ; D'Ambrosio R
Transplant Proc; 1991 Dec; 23(6):2732-5. PubMed ID: 1721260
[TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring.
Winkler M; Wonigeit K; Undre N; Ringe B; Oldhafer K; Christians U; Pichlmayr R
Transplant Proc; 1995 Feb; 27(1):822-5. PubMed ID: 7533433
[No Abstract] [Full Text] [Related]
4. The use of plasma levels for FK 506 dosing in liver-grafted patients.
Winkler M; Ringe B; Rodeck B; Melter M; Stoll K; Baumann J; Wonigeit K; Pichlmayr R
Transpl Int; 1994 Aug; 7(5):329-33. PubMed ID: 7527638
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a new immunoassay for therapeutic drug monitoring of tacrolimus in adult liver transplant recipients.
Marubashi S; Nagano H; Kobayashi S; Eguchi H; Takeda Y; Tanemura M; Umeshita K; Monden M; Doki Y; Mori M
J Clin Pharmacol; 2010 Jun; 50(6):705-9. PubMed ID: 20097937
[TBL] [Abstract][Full Text] [Related]
6. Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods.
Akbas SH; Ozdem S; Caglar S; Tuncer M; Gurkan A; Yucetin L; Senol Y; Demirbas A; Gultekin M; Ersoy FF; Akaydin M
Clin Biochem; 2005 Jun; 38(6):552-7. PubMed ID: 15885236
[TBL] [Abstract][Full Text] [Related]
7. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
8. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients.
Firdaous I; Hassoun A; Otte JB; Reding R; Squifflet JP; Besse T; Wallemacq PE
Clin Chem; 1995 Sep; 41(9):1292-6. PubMed ID: 7544705
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multiplied immunoassay methods.
Bartlomiejczyk I; Zochowska D; Sanko-Resmer J; Matuszewicz D; Paczek L
Transplant Proc; 2006; 38(1):94-6. PubMed ID: 16504673
[TBL] [Abstract][Full Text] [Related]
10. Validation and quality assurance program for monitoring tacrolimus (FK 506) concentrations in plasma and whole blood.
D'Ambrosio R; Girzaitis N; Jusko WJ
Ther Drug Monit; 1993 Oct; 15(5):414-26. PubMed ID: 7504339
[TBL] [Abstract][Full Text] [Related]
11. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group.
Transplant Proc; 1991 Dec; 23(6):3085-8. PubMed ID: 1721367
[No Abstract] [Full Text] [Related]
12. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation.
Tolou-Ghamari Z; Wendon J; Tredger JM
Clin Chem Lab Med; 2000 Nov; 38(11):1209-11. PubMed ID: 11156362
[TBL] [Abstract][Full Text] [Related]
13. Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients.
Rudant E; Bezie Y; Bonhomme-Faivre L; Manuel N; Rucay P; Fredj G; Bismuth H
J Clin Pharm Ther; 1997 Apr; 22(2):135-40. PubMed ID: 9373812
[TBL] [Abstract][Full Text] [Related]
14. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Shenoy S; Hardinger KL; Crippin J; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
Liver Transpl; 2008 Feb; 14(2):173-80. PubMed ID: 18236391
[TBL] [Abstract][Full Text] [Related]
15. More on the reliability of the microparticle enzyme immunoassay (MEIA) for therapeutic tacrolimus monitoring.
Hermida J; Tutor JC
Clin Lab; 2003; 49(9-10):471-4. PubMed ID: 14572203
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Richards TM; Crotty PH; Beaver SJ; Steers JL; Wiesner RH
Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different assays for the quantitation of FK 506 levels in blood or plasma.
Winkler M; Christians U; Stoll K; Baumann J; Pichlmayr R
Ther Drug Monit; 1994 Jun; 16(3):281-6. PubMed ID: 7521978
[TBL] [Abstract][Full Text] [Related]
18. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
[TBL] [Abstract][Full Text] [Related]
19. FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation.
Ross DJ; Lewis MI; Kramer M; Vo A; Kass RM
Chest; 1997 Nov; 112(5):1175-9. PubMed ID: 9367453
[TBL] [Abstract][Full Text] [Related]
20. Low plasma concentrations of albumin influence the affinity column-mediated immunoassay method for the measurement of tacrolimus in blood during the early period after liver transplantation.
Tempestilli M; Di Stasio E; Basile MR; Elisei F; Antonini M; Ettorre GM; Iappelli M; Pucillo LP
Ther Drug Monit; 2013 Feb; 35(1):96-100. PubMed ID: 23191996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
